DRAIN-HF: Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure

Status: Recruiting
Location: See all (46) locations...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Aortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure (ADHF) and have persistent congestion despite usual medical therapy. Eligible ADHF patients with diuretic resistance (irrespective of ejection fraction) will be enrolled and randomized 1:1 to either the Aortix system or standard of care medical management.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 21
Healthy Volunteers: f
View:

• Currently admitted to the hospital with a primary diagnosis of decompensated heart failure, irrespective of ejection fraction (EF);

• Patients should be on maximally tolerated diuretic therapy and not diuresing sufficiently before being enrolled in DRAIN-HF. After being up-titrated on diuretics, patients should be followed for at least 24 hours on the higher of: i) furosemide 80 mg IV bid or equivalent or ii) IV furosemide or equivalent IV loop diuretic at a dose 2.5 x total daily home dose of furosemide equivalents in 2 divided doses, as tolerated, patient must have: Urine Output \<1,500mL in a 12-hour period OR a Net Fluid Loss ≤375mL in a 12-hour period.

• Persistent signs and/or symptoms of congestion as evidenced by at least 2+ pitting edema, elevated jugular venous pressure \>12 cm water or ascites after treatment with IV diuretics per inclusion criterion 2.;

• Age \>21 years and able to provide written informed consent;

• Negative pregnancy test if patient is of child-bearing potential.

• Currently admitted to the hospital with a primary diagnosis of decompensated HF, irrespective of ejection fraction (EF).

• Patient has already been evaluated and indicated to receive an LVAD or heart transplant and will receive the LVAD or be listed for heart transplantation in the next 30 days if their congestion status and renal function improves.

• Patient must have been treated with ≥ 80 mg IV furosemide bid or equivalent and have evidence of increasing diuretic dosing requirements over the past 12 months, as tolerated.

• Must have evidence of refractoriness to medical management as documented by persistent signs and/or symptoms of congestion as evidenced by at least 2+ pitting edema, elevated jugular venous pressure \>12 cm water, or ascites after treatment with IV diuretics for a minimum of 24 hours.

• Serum creatinine ≥ 2.0 mg/dL AND eGFR ≤ 45 ml/min/1.73m2 at time of enrollment

• Age ≥ 21 years and able to provide written informed consent.

• Negative pregnancy test if patient is of childbearing potential.

Locations
United States
Arizona
Banner--University Medical Center Phoenix
RECRUITING
Phoenix
Mayo Clinic - Arizona
RECRUITING
Phoenix
HonorHealth Medical Center
ACTIVE_NOT_RECRUITING
Scottsdale
California
John Muir Health
RECRUITING
Concord
San Francisco Veterans Administration
RECRUITING
San Francisco
University of California San Francisco
RECRUITING
San Francisco
Zuckerberg San Francisco General
RECRUITING
San Francisco
Florida
Ascension Sacred Heart
WITHDRAWN
Pensacola
Tallahassee Research Institute
RECRUITING
Tallahassee
AdventHealth Tampa
RECRUITING
Tampa
BayCare Medical/St. Joseph's Hospital
RECRUITING
Tampa
University of South Florida
RECRUITING
Tampa
Cleveland Clinic Florida
RECRUITING
Weston
Georgia
Emory University Hospital
RECRUITING
Atlanta
Piedmont Healthcare Inc.
RECRUITING
Augusta
Wellstar Research Institue
RECRUITING
Marietta
Illinois
Advocate IMMC
RECRUITING
Chicago
University of Chicago
RECRUITING
Chicago
Advocate Aurora - Good Samaritan
RECRUITING
Downers Grove
Kansas
Ascension via Christi Kansas
RECRUITING
Wichita
Michigan
University of Michigan, Cardiovascular Medicine
ACTIVE_NOT_RECRUITING
Ann Arbor
Henry Ford
RECRUITING
Detroit
Mississippi
University of Mississippi Medical Center
RECRUITING
Jackson
North Carolina
Atrium Health Sanger Heart and Vascular Institute
RECRUITING
Charlotte
Duke University Medical Center
RECRUITING
Durham
Novant Health New Hanover Regional Medical Center
RECRUITING
Wilmington
New Jersey
Jersey Shore University Medical Center
RECRUITING
Neptune City
New York
New York Presbyterian - Brooklyn Methodist Hospital
RECRUITING
Brooklyn
Mount Sinai Morningside
RECRUITING
New York
Northwell Health (Lenox Hill)
TERMINATED
New York
Nyph/Cumc
RECRUITING
New York
Nuvance Health
RECRUITING
Poughkeepsie
Northwell Health (Staten Island)
RECRUITING
Staten Island
Ohio
The Ohio State University
RECRUITING
Columbus
Oklahoma
Oklahoma Cardiovascular Research Group
RECRUITING
Oklahoma City
Oregon
Oregon Health & Sciences University
ACTIVE_NOT_RECRUITING
Portland
Pennsylvania
Jefferson Abington Hospital
RECRUITING
Abington
Penn Presbyterian Medical Center
RECRUITING
Philadelphia
Thomas Jefferson University Hospital
RECRUITING
Philadelphia
Texas
Baylor Scott & White Research Institute
WITHDRAWN
Fort Worth
Texas Heart Institute
RECRUITING
Houston
Baylor Scott & White
WITHDRAWN
Plano
Utah
Intermountain Health
RECRUITING
Murray
Virginia
University of Virginia
TERMINATED
Charlottesville
Virginia Commonwealth University
RECRUITING
Richmond
Other Locations
Hungary
Semmelweis University
RECRUITING
Budapest
Contact Information
Primary
Rubi Reyes-Fuentez
rubi@procyrion.com
832-536-1601
Time Frame
Start Date: 2023-08-23
Estimated Completion Date: 2026-07
Participants
Target number of participants: 295
Treatments
Experimental: Treatment Arm
Eligible ADHF patients with diuretic resistance (irrespective of ejection fraction) will be enrolled and randomized 1:1 to either the Aortix system or standard of care medical management. Randomization will be stratified by ejection fraction.
No_intervention: Control Arm
The Control arm should receive standard of care therapy as per the study directed Diuretic Care Treatment Algorithm.
Experimental: Advanced HF Registry
For the Advanced HF registry, all eligible enrolled subjects will receive Aortix system support.
Related Therapeutic Areas
Sponsors
Leads: Procyrion

This content was sourced from clinicaltrials.gov